TIDES Europe: Oligonucleotide and Peptide Therapeutics is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Michael Keller, Ph.D.
Senior Principal Scientist, pRED, pCMC at Roche

Profile

Michael Keller studied Chemistry & Biochemistry at the ETH Zürich from 1989-1994. The award of the ETHZ-Imperial College London exchange scholarship 1994 enabled him to pursue a MSC/DIC in Chemical Research at Imperial College London, before joining the Research group of Professor Manfred Mutter at the University of Lausanne where he carried out a PhD in Bioorganic Chemistry. After a year as lecturer at the same Institute, he joined Imperial College London Genetic Therapies Centre as Academic Visitor specializing in nonviral delivery systems for nucleic acids. He co-founded the Anglo/Japanese Biotech company IC-Vec Ltd. in 2002 developing novel cationic lipids and nanomedicines for siRNA delivery, before joining Novartis Pharma AG Basel to build up siRNA formulation in Technical Research & Development. He was awarded the Novartis Leading Scientist Award in 2009 for his work on siRNA delivery. In late 2017 he joined the preclinical CMC unit at Hoffmann-La Roche Ltd. Basel to work on locked nucleic acids (LNAs), with a particular focus on disruptive concepts to enable enhanced delivery of LNA.

Michael Keller, Ph.D.'s Network

Agenda Sessions

  • Investigations into Disruptive Delivery Approaches for LNA Antisense Oligonucleotides (ASO LNA)

    , 13:45